Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085908 | 0.90 | HDAC8 (0.58) | HDAC8HDAC6HDAC11KCNA3HTR2C | |
| SCHEMBL5894379 | 0.87 | HDAC8 (0.56) | HDAC8HDAC6HDAC11HTR2CHDAC3 | |
| SCHEMBL12628329 | 0.87 | HDAC8 (0.56) | HDAC8HDAC6HDAC11KCNA3HTR2C | |
| SCHEMBL2156618 | 0.86 | HTR2C (0.56) | HDAC8HDAC6HDAC11KCNA3HTR2C | |
| SCHEMBL6087507 | 0.84 | HDAC8 (0.57) | HDAC8HDAC6HDAC11KCNA3HTR2C | |
| SCHEMBL9202051 | 0.84 | HTR2C (0.52) | HDAC8HDAC6HDAC11KCNA3HTR2C | |
| SCHEMBL6085962 | 0.83 | KDM4C (0.47) | HDAC8HDAC6HDAC11KCNA3HDAC3 | |
| SCHEMBL22533536 | 0.83 | HDAC6 (0.56) | HDAC8HDAC6HDAC11KCNA3HTR2C | |
| SCHEMBL9202057 | 0.82 | HDAC8 (0.46) | HDAC8HDAC6HDAC11KCNA3HTR2C | |
| SCHEMBL6086223 | 0.82 | HDAC8 (0.48) | HDAC8HDAC6HDAC11KCNA3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2008157740-A2 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-6987122-B2 | 2-(1H-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2006-01-17 | — | — | US | disclosed |
| EP-1244652-B1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS EUROPE SRL (IT) | 2005-08-24 | — | — | EP | disclosed |
| US-6753342-B2 | ANTICARCINOGENIC AGENTS FOR LUNG AND COLON CANCER TREATMENT | NOVUSPHARMA S.P.A. (IT) | 2004-06-22 | — | — | US | disclosed |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | NOVUSPHARMA S.P.A. (IT) | 2003-08-21 | — | — | US | disclosed |
| EP-1322646-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | Novuspharma S.p.A. (IT) | 2003-07-02 | — | — | EP | disclosed |
| EP-1244652-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002008225-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001047916-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | HDAC8 989/4885HDAC6 845/4885HDAC11 1757/4885 |
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | IDO2, IDO1, TXNRD2 | HDAC8 831/4885HDAC6 415/4885HDAC11 358/4885 |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | FAAH, FAAH2, AANAT | HDAC8 584/4885HDAC6 423/4885HDAC11 958/4885 |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | IDO1, AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HDAC8 78/4885HDAC6 21/4885HDAC11 29/4885 |
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | HDAC8 678/4885HDAC6 532/4885HDAC11 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.